hat
Estewoyid anabolizan / Androjenik ka gen efè negatif sou kolestewòl serom. Sa gen ladann yon tandans pou diminye valè kolestewòl HDL (bon) epi ogmante valè kolestewòl LDL (move), ki ka chanje HDL a nan balans LDL nan yon direksyon ki favorize pi gwo risk pou atè klerezè. Enpak relatif la nan yon esteroyid anabolizan / Androjenik sou lipid serik se depann sou dòz la, wout nan administrasyon (oral vs injectable), kalite esteroyid (aromatizable oswa ki pa aromatizable), ak nivo nan rezistans nan metabolis epatik. Methylandrostenediol gen yon efè fò sou jesyon an òmp nan kolestewòl akòz rezistans estriktirèl li yo nan pann fwa ak (ak oral la) wout nan administrasyon yo. Estewoyid anabolizan / Androjenik kapab tou negativman afekte san presyon ak trigliserid, diminye detant endopelik, ak sipò kite ipèrtrofi ventrikulèr, tout potansyèlman ogmante risk pou yo maladi kadyovaskilè ak enfaktis myokad.
eng
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Methylandrostenediol has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown and (with the oral) route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.